References
1. Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of
non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+
CD19-specific chimeric antigen receptor-modified T cells. Sci
Transl Med . 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric Antigen
Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J
Med . 2011;365(8):725-733. doi:10.1056/NEJMoa1103849
3. Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR-T cells of defined
CD4+:CD8+ composition in adult B cell ALL patients. J Clin
Invest . 2016;126(6):2123-2138. doi:10.1172/JCI85309
4. Maude SL, Frey N, Shaw PA, et al. Chimeric Antigen Receptor T Cells
for Sustained Remissions in Leukemia. N Engl J Med .
2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222
5. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy.J Hematol Oncol . 2017;10(1):53. doi:10.1186/s13045-017-0423-1
6. Kalos M, June CH. Adoptive T Cell Transfer for Cancer Immunotherapy
in the Era of Synthetic Biology. Immunity . 2013;39(1):49-60.
doi:10.1016/J.IMMUNI.2013.07.002
7. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the
integration of new DNA in the human genome. Nat Rev Cancer .
2011;12(1):nrc3179. doi:10.1038/nrc3179
8. Finer M, Dull T, Qin L, Farson D, Roberts M. kat: a high-efficiency
retroviral transduction system for primary human T lymphocytes.Blood . 1994;83(1).
9. Naldini L, Blömer U, Gallay P, et al. In Vivo Gene Delivery and
Stable Transduction of Nondividing Cells by a Lentiviral Vector.Science (80- ) . 272:263-267. doi:10.2307/2889637
10. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and
function of retroviral-modified chimeric antigen receptor T cells.Sci Transl Med . 2012;4(132):132ra53.
doi:10.1126/scitranslmed.3003761
11. Mitchell RS, Beitzel BF, Schroder ARW, et al. Retroviral DNA
Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences.
Michael Emerman, ed. PLoS Biol . 2004;2(8):e234.
doi:10.1371/journal.pbio.0020234
12. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M.
Viral vectors: a look back and ahead on gene transfer technology.New Microbiol . 2013;36(1):1-22.
13. Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of
CAR T Cell Therapy. Mol Ther Methods Clin Dev . 2017;4:92-101.
doi:10.1016/j.omtm.2016.12.006
14. Paludan SR, Bowie AG. Cellular & Gene Therapy Guidances -
Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects
for Delayed Adverse Events. US Dep Heal Hum Serv Food Drug Adm
Cent Biol Eval Res . 2006.
15. Gill S, June CH. Going viral: chimeric antigen receptor T-cell
therapy for hematological malignancies. Immunol Rev .
2015;263(1):68-89. doi:10.1111/imr.12243
16. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors
containing CD137 signal transduction domains mediate enhanced survival
of T cells and increased antileukemic efficacy in vivo. Mol Ther .
2009;17(8):1453-1464. doi:10.1038/mt.2009.83
17. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and
remissions of malignancy along with cytokine-associated toxicity in a
clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T
cells. Blood . 2012;119(12):2709-2720.
doi:10.1182/blood-2011-10-384388
18. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus
vector with a conditional packaging system. J Virol .
1998;72(11):8463-8471.
19. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric
antigen receptors that mediate constitutive or inducible proliferation
of T cells. Cancer Immunol Res . 2015;3(4):356-367.
doi:10.1158/2326-6066.CIR-14-0186
20. Zhao N, Qi J, Zeng Z, et al. Transfecting the hard-to-transfect
lymphoma/leukemia cells using a simple cationic polymer nanocomplex.J Control Release . 2012;159(1):104-110.
doi:10.1016/j.jconrel.2012.01.007
21. Mitchell DA, Karikari I, Cui X, Xie W, Schmittling R, Sampson JH.
Selective modification of antigen-specific T cells by RNA
electroporation. Hum Gene Ther . 2008;19(5):511-521.
doi:10.1089/hum.2007.115
22. Liu L, Johnson C, Fujimura S, Teque F, Levy JA. Transfection
optimization for primary human CD8+ cells. J Immunol Methods .
2011;372(1-2):22-29. doi:10.1016/J.JIM.2011.06.026
23. Ramamoorth M, Narvekar A. Non Viral Vectors in Gene Therapy- An
Overview. J Clin Diagn Res . 2015;9(1):GE01.
doi:10.7860/JCDR/2015/10443.5394
24. Zhang Z, Qiu S, Zhang X, Chen W. Optimized DNA electroporation for
primary human T cell engineering. BMC Biotechnol . 2018;18(1):4.
doi:10.1186/s12896-018-0419-0
25. Zhang Z, Qiu S, Zhang X, Chen W. Optimized electroporation of
Primary T cells. BMC Biotechnol . 2018;18(4):1-9.
26. Jordan ET, Collins M, Terefe J, Ugozzoli L, Rubio T. Optimizing
electroporation conditions in primary and other difficult-to-transfect
cells. J Biomol Tech . 2008;19(5):328-334.
27. Goffinet C, Keppler OT. Efficient nonviral gene delivery into
primary lymphocytes from rats and mice. FASEB J .
2006;20(3):500-502. doi:10.1096/fj.05-4651fje
28. Ross PC, Hui SW. Lipoplex size is a major determinant of in vitro
lipofection efficiency. Gene Ther . 1999;6(4):651-659.
doi:10.1038/sj.gt.3300863
29. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape
pathways for delivery of biologicals. J Control Release .
2011;151(3):220-228. doi:10.1016/j.jconrel.2010.11.004
30. Mašek T, Vopalenský V, Pospíšek M. The Luc2 gene enhances
reliability of bicistronic assays. Open Life Sci .
2013;8(5):423-431. doi:10.2478/s11535-013-0151-z
31. Conese M, Biffi A, Dina G, Marziliano N, Villa A. Comparison between
Cationic Polymer and Lipid in Plasmidic DNA Delivery to the Cell
Nucleus. Open Gene Ther J . 2009;2:21-28.
32. Bragonzi A, Boletta A, Biffi A, et al. Comparison between cationic
polymers and lipids in mediating systemic gene delivery to the lungs.Gene Ther . 1999;6(12):1995-2004. doi:10.1038/sj.gt.3301039
33. Ayoubi TA, Van De Ven WJ. Regulation of gene expression by
alternative promoters. FASEB J . 1996;10(4):453-460.
34. Qin JY, Zhang L, Clift KL, et al. Systematic comparison of
constitutive promoters and the doxycycline-inducible promoter.PLoS One . 2010;5(5):e10611. doi:10.1371/journal.pone.0010611
35. Chung S, Andersson T, Sonntag K-C, Björklund L, Isacson O, Kim K-S.
Analysis of different promoter systems for efficient transgene
expression in mouse embryonic stem cell lines. Stem Cells .
2002;20(2):139-145. doi:10.1634/stemcells.20-2-139
36. Lacy-Hulbert A, Thomas R, Li X-P, Lilley CE, Coffin RS, Roes J.
Interruption of coding sequences by heterologous introns can enhance the
functional expression of recombinant genes. Gene Ther .
2001;8(8):649-653. doi:10.1038/sj.gt.3301440
37. Christensen MD, Elmer JJ, Eaton S, Gonzalez-Malerva L, LaBaer J,
Rege K. Kinome-level screening identifies inhibition of polo-like
kinase-1 (PLK1) as a target for enhancing non-viral transgene
expression. J Control Release . 2015;204:20-29.
doi:10.1016/j.jconrel.2015.01.036
38. Sutlu T, Nyström S, Gilljam M, Stellan B, Applequist SE, Alici E.
Inhibition of Intracellular Antiviral Defense Mechanisms Augments
Lentiviral Transduction of Human Natural Killer Cells: Implications for
Gene Therapy. Hum Gene Ther . 2012;23(10):1090-1100.
doi:10.1089/hum.2012.080
39. Chen Z-Y, Riu E, He C-Y, Xu H, Kay M a. Silencing of episomal
transgene expression in liver by plasmid bacterial backbone DNA is
independent of CpG methylation. Mol Ther . 2008;16(3):548-556.
doi:10.1038/sj.mt.6300399
40. Chen Z. Minicircle DNA vectors devoid of bacterial DNA result in
persistent and high-level transgene expression in vivo. Mol Ther .
2003;8(3):495-500. doi:10.1016/S1525-0016(03)00168-0
41. Audouy S, Molema G, de Leij L, Hoekstra D. Serum as a modulator of
lipoplex-mediated gene transfection: dependence of amphiphile, cell type
and complex stability. J Gene Med . 2000;2(6):465-476.
doi:10.1002/1521-2254(200011/12)2:6<465::AID-JGM141>3.0.CO;2-Z
42. Yang J-P, Huang L. Overcoming the Inhibitory Effect of Serum
on Lipofection by Increasing the Charge Ratio of Cationic Liposome to
DNA . Vol 4.; 1997.
43. Joshee N, Bastola DR, Cheng P-W. Transferrin-Facilitated
Lipofection Gene Delivery Strategy: Characterization of the Transfection
Complexes and Intracellular Trafficking . Vol 13.; 2002.
www.liebertpub.com. Accessed August 21, 2019.
44. Yanagihara K, Cheng H, Cheng P-W. Effects of epidermal growth
factor, transferrin, and insulin on lipofection efficiency in human lung
carcinoma cells. Cancer Gene Ther . 2000;7(1):59-65.
doi:10.1038/sj.cgt.7700092
45. Olden BR, Cheng Y, Yu JL, Pun SH. Cationic polymers for non-viral
gene delivery to human T cells. J Control Release .
2018;282:140-147. doi:10.1016/j.jconrel.2018.02.043
46. Van Tendeloo VFI, Willems R, Ponsaerts P, et al. High-level
transgene expression in primary human T lymphocytes and adult bone
marrow CD34+ cells via electroporation-mediated gene delivery.Gene Ther . 2000;7(16):1431-1437. doi:10.1038/sj.gt.3301252
47. Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An Efficient Low Cost
Method for Gene Transfer to T Lymphocytes. Fang D, ed. PLoS One .
2013;8(3):e60298. doi:10.1371/journal.pone.0060298
48. Zhao Y, Zheng Z, Cohen CJ, et al. High-Efficiency Transfection of
Primary Human and Mouse T Lymphocytes Using RNA Electroporation.Mol Ther . 2006;13(1):151-159. doi:10.1016/J.YMTHE.2005.07.688
49. Meaking WS, Edgerton J, Wharton CW, Meldrum RA.
Electroporation-induced damage in mammalian cell DNA. BBA - Gene
Struct Expr . 1995;1264(3):357-362. doi:10.1016/0167-4781(95)00177-8
50. Piñero J, López-Baena M, Ortiz T, Cortés F. Apoptotic and
Necrotic Cell Death Are Both Induced by Electroporation in HL60 Human
Promyeloid Leukaemia Cells . Vol 2.; 1997.
51. Ortiz T, Piñero J, Cortés F. Chromosome damage induced by combined
treatments with restriction endonucleases introduced into CHO cells by
single or double electroporation. Mutat Res - Fundam Mol Mech
Mutagen . 1995;327(1-2):161-169. doi:10.1016/0027-5107(94)00183-6
52. Lesueur L, Mir LM, Andr FM. Overcoming the Specific Toxicity of
Large Plasmids Electrotransfer in Primary Cells In Vitro. 2016.
doi:10.1038/mtna.2016.4
53. Pradhan K, Gadgil M. Effect of addition of “carrier” DNA during
transient protein expression in suspension CHO culture.Cytotechnology . 2012;64(6):613-622. doi:10.1007/s10616-012-9435-4
54. Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H. Innate
immune response induced by gene delivery vectors. Int J Pharm .
2008;354(1-2):9-15. doi:10.1016/j.ijpharm.2007.06.012
55. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of
RNase L in innate immunity. J Interferon Cytokine Res .
2011;31(1):49-57. doi:10.1089/jir.2010.0120
56. Atianand MK, Fitzgerald KA. Molecular basis of DNA recognition in
the immune system. J Immunol . 2013;190(5):1911-1918.
doi:10.4049/jimmunol.1203162
57. Christianson HC, Belting M. Heparan sulfate proteoglycan as a
cell-surface endocytosis receptor. Matrix Biol . 2014;35:51-55.
doi:10.1016/j.matbio.2013.10.004
58. Teixé T, Nieto-Blanco P, Vilella R, Engel P, Reina M, Espel E.
Syndecan-2 and -4 expressed on activated primary human CD4+ lymphocytes
can regulate T cell activation. Mol Immunol .
2008;45(10):2905-2919. doi:10.1016/j.molimm.2008.01.033
59. Fadnes B, Husebekk A, Svineng G, et al. The proteoglycan repertoire
of lymphoid cells. Glycoconj J . 2012;29(7):513-523.
doi:10.1007/s10719-012-9427-9
60. Subramanian Vignesh K, Deepe GS, Jr. Metallothioneins: Emerging
Modulators in Immunity and Infection. Int J Mol Sci . 2017;18(10).
doi:10.3390/ijms18102197
61. Rice JM, Zweifach A, Lynes MA. Metallothionein regulates
intracellular zinc signaling during CD4 + T cell activation. 2016.
doi:10.1186/s12865-016-0151-2
62. Wu C, Pot C, Apetoh L, et al. Metallothioneins negatively regulate
IL-27-induced type 1 regulatory T-cell differentiation. Proc Natl
Acad Sci U S A . 2013;110(19):7802-7807. doi:10.1073/pnas.1211776110
63. Doitsh G, Galloway NLK, Geng X, et al. Cell death by pyroptosis
drives CD4 T-cell depletion in HIV-1 infection. Nature .
2014;505(7484):509-514. doi:10.1038/nature12940
64. Muñoz-Arias I, Doitsh G, Yang Z, Sowinski S, Ruelas D, Greene WC.
Blood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive
HIV-1 Infection. Cell Host Microbe . 2015;18(4):463-470.
doi:10.1016/j.chom.2015.09.010
65. Ng YC, Chung W-C, Kang H-R, et al. A DNA-sensing-independent role of
a nuclear RNA helicase, DHX9, in stimulation of NF-B-mediated innate
immunity against DNA virus infection. Nucleic Acids Res .
2018;46(17):9011-9026. doi:10.1093/nar/gky742
66. Zhang X, Brann TW, Zhou M, et al. Cutting Edge: Ku70 Is a Novel
Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN.J Immunol . 2011;186(8):4541-4545. doi:10.4049/jimmunol.1003389
67. Letoha T, Keller-Pintér A, Kusz E, et al. Cell-penetrating peptide
exploited syndecans. Biochim Biophys Acta - Biomembr .
2010;1798(12):2258-2265. doi:10.1016/j.bbamem.2010.01.022
68. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS.
Promoter attenuation in gene therapy: Interferon-γ and tumor necrosis
factor-α inhibit transgene expression. Hum Gene Ther .
1997;8(17):2019-2029. doi:10.1089/hum.1997.8.17-2019
69. Pine R. Constitutive expression of an ISGF2/IRF1 transgene leads to
interferon-independent activation of interferon-inducible genes and
resistance to virus infection. J Virol . 1992;66(7):4470-4478.
doi:10.1128/jvi.66.7.4470-4478.1992
70. Sellins K, Fradkin L, Liggitt D, Dow S. Type I interferons potently
suppress gene expression following gene delivery using liposome-DNA
complexes. Mol Ther . 2005;12(3):451-459.
doi:10.1016/j.ymthe.2005.04.008
71. Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the piggybac
transposon system for the sustained genetic modification of human T
lymphocytes. J Immunother . 2009;32(8):826-836.
doi:10.1097/CJI.0b013e3181ad762b
72. Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell
function and specificity with non-viral genome targeting. Nature .
2018;559(7714):405-409. doi:10.1038/s41586-018-0326-5
73. Olden BR, Cheng E, Cheng Y, Pun SH. Identifying key barriers in
cationic polymer gene delivery to human T cells. Biomater Sci .
2019;7(3):789-797. doi:10.1039/c8bm01262h
74. Pampusch MS, Haran KP, Hart GT, et al. Rapid Transduction and
Expansion of Transduced T Cells with Maintenance of Central Memory
Populations. Mol Ther - Methods Clin Dev . 2020;16:1-10.
doi:10.1016/j.omtm.2019.09.007
75. Tumeh PC, Koya RC, Chodon T, et al. The impact of ex vivo clinical
grade activation protocols on human T cell phenotype and function for
the generation of genetically modified cells for adoptive cell transfer
therapy. J Immunother . 2010;33(8):759-768.
doi:10.1097/CJI.0b013e3181f1d644
76. Bai H, Lester GMS, Petishnok LC, Dean DA. Cytoplasmic transport and
nuclear import of plasmid DNA. Biosci Rep . 2017;37(6).
doi:10.1042/BSR20160616
77. Bobardt MD, Armand-Ugón M, Clotet I, et al. Effect of
polyanion-resistance on HIV-1 infection. Virology .
2004;325(2):389-398. doi:10.1016/j.virol.2004.05.011
78. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans.Cold Spring Harb Perspect Biol . 2011;3(7):1-33.
doi:10.1101/cshperspect.a004952
79. Spillmann D. Heparan sulfate: anchor for viral intruders?Biochimie . 2001;83(8):811-817. doi:10.1016/s0300-9084(01)01290-1
80. Bastien Paris S, Burlacu A, Durocher Y. Opposing Roles of Syndecan-1
and Syndecan-2 in Polyethyleneimine-mediated Gene Delivery * □ S. 2008.
doi:10.1074/jbc.M705424200
81. Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with
CD19-specific chimeric antigen receptor (CAR)-modified T cells in
children with relapsed/refractory ALL. J Clin Oncol.
2016;34(15_suppl):3011-3011. doi:10.1200/jco.2016.34.15_suppl.3011
82. Moffett, H. F., Coon, M. E., Radtke, S., Stephan, S. B., McKnight,
L., Lambert, A., Stoddard, B. L., Kiem, H. P. & Stephan, M. T.
Hit-and-run programming of therapeutic cytoreagents using mRNA
nanocarriers. Nat. Commun. 8, 1–13 (2017).
83. Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji,
W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S. &
Stephan, M. T. In situ programming of leukaemia-specific t cells using
synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–822 (2017).
84. Raup, A., Stahlschmidt, U., Jérôme, V., Synatschke, C., Müller, A.
& Freitag, R. Influence of Polyplex Formation on the Performance of
Star-Shaped Polycationic Transfection Agents for Mammalian Cells.
Polymers (Basel). 8, 224 (2016).
85. Schallon, A., Synatschke, C. V., Jérôme, V., Müller, A. H. E. &
Freitag, R. Nanoparticulate nonviral agent for the effective delivery of
pDNA and siRNA to differentiated cells and primary human T lymphocytes.
Biomacromolecules 13, 3463–3474 (2012).
85. Xie, Y., Kim, N. H., Nadithe, V., Schalk, D., Thakur, A., Kılıç, A.,
Lum, L. G., Bassett, D. J. P. & Merkel, O. M. Targeted delivery of
siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as
a potential therapy of asthma. J. Control. Release 229, 120–129 (2016).
87. Olden, B. R., Cheng, Y., Yu, J. L. & Pun, S. H. Cationic polymers
for non-viral gene delivery to human T cells. J. Control. Release 282,
140–147 (2018).